Karijn Suijkerbuijk is a translational medical oncologist with special interest in melanoma and immunotherapy. Her current research focuses on clinical and immunological parameters assoaciated with immune related adverse events during checkpoint inhibition and clinicopathological factors associated with checkpoint inhibitor response. Karijn works at the UMC Utrecht.